DWI/ADC in response assessment after local-regional treatment of HCC - Pearls and Pitfalls
- PMID: 40347825
- DOI: 10.1016/j.ejrad.2025.112156
DWI/ADC in response assessment after local-regional treatment of HCC - Pearls and Pitfalls
Abstract
Many patients with hepatocellular carcinoma (HCC) present with advanced-stage disease or multifocal tumors which make them unsuitable for radical treatment options. In such cases, locoregional therapy (LRT) such as transarterial chemoembolization (TACE), transarterial radioembolization (TARE) can be used as a bridge to liver transplantation or to downstage borderline tumors. However, post treatment response assessment can be very difficult, especially in the case of TARE. The recently updated Liver Imaging Reporting and Data System treatment response algorithm (LI-RADS TRA) 2024 guidelines has included ancillary features of mild-moderate T2 signal intensity and diffusion restriction into the assessment algorithm. Diffusion-weighted imaging (DWI) would be particularly important in post-TARE assessment as early response assessment using traditional size and enhancement criteria can be challenging following TARE. However, the interpretation of restricted diffusion in post-treatment imaging can be challenging as DWI can be affected by various factors such as inflammatory changes, haemorrhage, or T2-relaxation time of the surrounding parenchyma. In this review article, we provide an overview of the advantages and challenges in the use of DWI to interpret treatment response after LRT.
Keywords: Hepatocellular Carcinoma; Liver; Magnetic Resonance Imaging.
Copyright © 2025 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.Abdom Radiol (NY). 2024 Sep;49(9):3045-3055. doi: 10.1007/s00261-024-04275-y. Epub 2024 Apr 11. Abdom Radiol (NY). 2024. PMID: 38605217
-
Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.J Hepatol. 2017 Dec;67(6):1213-1221. doi: 10.1016/j.jhep.2017.07.030. Epub 2017 Aug 18. J Hepatol. 2017. PMID: 28823713
-
Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation.Abdom Radiol (NY). 2019 Aug;44(8):2740-2750. doi: 10.1007/s00261-019-02030-2. Abdom Radiol (NY). 2019. PMID: 31069479
-
Multifocal hepatocellular carcinoma: a narrative review assessing treatment options from the interventional radiologist's perspective.Ann Palliat Med. 2023 Nov;12(6):1244-1259. doi: 10.21037/apm-23-294. Epub 2023 Aug 9. Ann Palliat Med. 2023. PMID: 37574584 Review.
-
Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.Hepatol Int. 2016 Nov;10(6):883-892. doi: 10.1007/s12072-016-9722-9. Epub 2016 Apr 28. Hepatol Int. 2016. PMID: 27126821 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous